Experimental Parkinson's drug talineuren put to early safety test

NCT ID NCT04976127

Terminated Disease control Sponsor: InnoMedica Schweiz AG Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested the safety of an intravenous drug called talineuren (liposomal GM1) in 22 people with Parkinson's disease. The study was open-label and designed to find a safe dose, but it was terminated before completion. No conclusions about effectiveness can be drawn from this small, preliminary study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: talineuren (liposomal GM1)
What this could lead to: If successful, this could point toward a new add-on therapy to help manage Parkinson's symptoms alongside standard treatment.
What could go wrong: This was a very early Phase 1 safety trial with only 22 participants, and it was terminated early. It is too small and preliminary to draw any conclusions about effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Neurologisches Institut Konolfingen

Konolfingen, Canton of Bern, 3510, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.